基线前列腺特异性抗原与前列腺癌检出及前列腺癌死亡的关系:欧洲前列腺癌筛查随机研究长期随访
基于欧洲前列腺癌筛查随机研究(ERSPC)筛查臂16年随访数据,分析25589名55-59岁、16898名60-64岁和12936名65-69岁男性首次PSA水平与前列腺癌检出及前列腺癌特异性死亡的关系,发现基线PSA可指导重复筛查间隔,基线PSA<1.0 ng/ml是延迟或停止进一步筛查的强指标。
要点
- 16年时任何前列腺癌的总体 actuarial 概率为12%-16%,临床显著前列腺癌为3.7%-5.7%。
- 基线PSA<1.0 ng/ml男性16年临床显著前列腺癌概率为1.2%-1.5%,PSA≥3.0 ng/ml为13.3%-13.8%。
- 60-61岁男性中92%致死性前列腺癌发生于基线PSA高于中位数(1.21 ng/ml)者。
核心结论
- 在所有年龄组中,基线PSA可指导重复筛查间隔的决策。
- 55-69岁男性基线PSA<1.0 ng/ml是延迟或停止进一步筛查的强指标。
研究设计与样本
- 评估欧洲前列腺癌筛查随机研究(ERSPC)筛查臂中25589名55-59岁、16898名60-64岁和12936名65-69岁至少参加一次筛查访视的男性,随访16年;筛查臂每2-4年重复PSA检测并对PSA升高者行活检,对照臂不提供主动筛查。
主要发现
- 16年时任何前列腺癌的总体 actuarial 概率在各年龄组为12%-16%,临床显著前列腺癌(Gleason≥7)为3.7%-5.7%。
- 16年时临床显著前列腺癌的 actuarial 概率在PSA<1.0 ng/ml男性为1.2%-1.5%,在PSA≥3.0 ng/ml男性为13.3%-13.8%。
- 基线PSA与前列腺癌特异性死亡之间的关联在三个年龄组间差异 marginal。
- 60-61岁男性Lorenz曲线显示92%的致死性前列腺癌病例发生于基线PSA高于中位数(1.21 ng/ml)者。
- 对于60-61岁首次筛查且基线PSA<2 ng/ml的男性,若PSA仍<2 ng/ml,在68-70岁后继续筛查不太可能获益;随后8年(至76-78岁)未出现前列腺癌特异性死亡病例。
关键数值与推荐
- 16年时任何前列腺癌 actuarial 概率12%-16%,临床显著前列腺癌3.7%-5.7%。
- 16年时临床显著前列腺癌 actuarial 概率:PSA<1.0 ng/ml组1.2%-1.5%,PSA≥3.0 ng/ml组13.3%-13.8%。
- 60-61岁男性基线PSA中位数为1.21 ng/ml,92%致死性前列腺癌发生于高于该中位数者。
临床怎么用
- 原文未据此给出推荐。
局限性
- 这些结果可能无法推广至机会性筛查环境或当代临床实践。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The European Association of Urology guidelines recommend a risk-based strategy for prostate cancer screening based on the first prostate-specific antigen (PSA) level and age. OBJECTIVE: To analyze the impact of the first PSA level on prostate cancer (PCa) detection and PCa-specific mortality (PCSM) in a population-based screening trial (repeat screening every 2-4 yr). DESIGN, SETTING, AND PARTICIPANTS: We evaluated 25589 men aged 55-59 yr, 16898 men aged 60-64 yr, and 12936 men aged 65-69 yr who attended at least one screening visit in the European Randomized Study of Screening for Prostate Cancer (ERSPC) trial (screening arm: repeat PSA testing every 2-4 yr and biopsy in cases with elevated PSA; control arm: no active screening offered) during 16-yr follow-up (FU). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We assessed the actuarial probability for any PCa and for clinically significant (cs)PCa (Gleason ≥7). Cox proportional-hazards regression was performed to assess whether the association between baseline PSA and PCSM was comparable for all age groups. A Lorenz curve was computed to assess the association between baseline PSA and PCSM for men aged 60-61 yr. RESULTS AND LIMITATIONS: The overall actuarial probability at 16 yr ranged from 12% to 16% for any PCa and from 3.7% to 5.7% for csPCa across the age groups. The actuarial probability of csPCa at 16 yr ranged from 1.2-1.5% for men with PSA <1.0 ng/ml to 13.3-13.8% for men with PSA ≥3.0 ng/ml. The association between baseline PSA and PCSM differed marginally among the three age groups. A Lorenz curve for men aged 60-61 yr showed that 92% of lethal PCa cases occurred among those with PSA above the median (1.21 ng/ml). In addition, for men initially screened at age 60-61 yr with baseline PSA <2 ng/ml, further continuation of screening is unlikely to be beneficial after the age of 68-70 yr if PSA is still <2 ng/ml. No case of PCSM emerged in the subsequent 8 yr (up to age 76-78 yr). A limitation is that these results may not be generalizable to an opportunistic screening setting or to contemporary clinical practice. CONCLUSIONS: In all age groups, baseline PSA can guide decisions on the repeat screening interval. Baseline PSA of <1.0 ng/ml for men aged 55-69 yr is a strong indicator to delay or stop further screening. PATIENT SUMMARY: In prostate cancer screening, the patient's baseline PSA (prostate-specific antigen) level can be used to guide decisions on when to repeat screening. The PSA test when used according to current knowledge is valuable in helping to reduce the burden of prostate cancer.
引用
- Remmers S, Bangma CH, Godtman RA, et al. Relationship Between Baseline Prostate-specific Antigen on Cancer Detection and Prostate Cancer Death: Long-term Follow-up from the European Randomized Study of Screening for Prostate Cancer. Eur Urol. 2023. PMID: 37088597. doi:10.1016/j.eururo.2023.03.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。